Last reviewed · How we verify
I-123 mIBG
I-123 mIBG binds to norepinephrine transporters
I-123 mIBG binds to norepinephrine transporters Used for Thyroid cancer.
At a glance
| Generic name | I-123 mIBG |
|---|---|
| Sponsor | GE Healthcare |
| Drug class | Radioligand |
| Target | Norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
I-123 mIBG is a radioligand that selectively binds to norepinephrine transporters in the body, allowing for imaging of these transporters in various conditions.
Approved indications
- Thyroid cancer
Common side effects
Key clinical trials
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (PHASE1, PHASE2)
- Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma (PHASE2)
- Terazosin Effect on Cardiac Changes in Early Parkinson's Disease (PHASE2)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Mental Stress Reactivity in Women With CMD (NA)
- Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma (PHASE1, PHASE2)
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (PHASE2)
- Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- I-123 mIBG CI brief — competitive landscape report
- I-123 mIBG updates RSS · CI watch RSS
- GE Healthcare portfolio CI